首页 | 本学科首页   官方微博 | 高级检索  
     


Brexit threatens the UK’s ability to tackle illicit drugs and organised crime: What needs to happen now?
Authors:Andres Roman-Urrestarazu  Justin Yang  Roy Robertson  Alison McCallum  Christina Gray  Martin McKee  John Middleton
Affiliation:1. Institute of Public Health, University of Cambridge, Cambridge, United Kingdom;2. Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom;3. Public Health and Health Policy, NHS Lothian, United Kingdom;4. Faculty of Public Health Special Interest Group for Mental Health, United Kingdom;5. Faculty of Health and Applied Social Sciences, University of the West of England, United Kingdom;6. London School of Hygiene and Tropical Medicine, London, United Kingdom;7. President UK Faculty of Public Health, London, United Kingdom
Abstract:BackgroundThe decision by the UK government to leave the European Union comes at a time when parts of the UK are experiencing a marked rise in reported gun and knife crimes. The health effects of Brexit will have serious consequences as to how the UK tackles this upsurge in drug-related crime.Health policy processesThe UK’s future participation with the EU’s specialised agencies will depend on the detail of any agreement reached on future collaboration with the EU and its drug agency, the EMCDDA.ContextThe EMCDDA provides the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support debates on drugs policies. It also supports early warning initiatives and coordinates measures at national and supranational levels with Europol and supranational enforcement agencies.Expected outcomesWhile these arrangements might continue throughout any transition period, those working within the sector require guidance and assurances from the British government about its long-term intentions after any transition.ConclusionsThe scale of collaboration between the UK and European institutions is extensive. It is not clear how this might be replicated after Brexit. Yet an alternative framework of collaboration between the UK and the EU is clearly needed to facilitate shared and agreed approaches to data sharing and drug surveillance after Brexit.
Keywords:Corresponding author.  Brexit  EMCDDA  Drug policy  Substance abuse  Early warning  Health systems post-Brexit  Public health
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号